Please sign in to follow a disease.
Can an injection melt away belly fat for good?
NCT ID NCT07733947
First seen Jul 29, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This trial is testing whether an experimental injection called CBL-514 can safely reduce stubborn belly fat. It is for people who already received the treatment or a placebo in an earlier study. Researchers are checking for side effects and whether fat reduction lasts over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- an experimental injection called CBL-514
- What this could lead to
- If it works, this could offer a non-surgical option for reducing stubborn belly fat.
- What could go wrong
- This is a follow-up study focused on safety and lasting effects, not on proving the treatment works. Side effects from the injections are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Participant must have received at least 1 treatment of CBL 514 or Placebo and completed the FU1 visit of the parent study. 2. Participant is willing to maintain a stable lifestyle. 3. Participant voluntarily signs the Informed Consent Form (ICF) for Stage 1 and, in the opinion of the Investigator or delegate, is physically and mentally capable of participating in the study, and willing to adhere to the study procedures. Exclusion Criteria: 1. Participant has had or will be undergoing treatment that may affect the evaluation of the treated area. 2. Participant is taking prescription or over the counter (OTC) weight reduction medication or is in a weight reduction program. 3. Participant has an unstable condition or is otherwise thought to be unreliable or incapable of complying with the requirements of the protocol. 4. Female participant of childbearing potential who is not willing to commit to an acceptable contraceptive method or who is currently pregnant or lactating. Male participant who is not committed to using condoms consistently throughout the study. Ova and sperm donation are to occur after a certain washout period post IP treatment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Subcutaneous fat are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Investigational site 1
Encinitas, California, 92024, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.